Clive Dix receives the Scrip Lifetime Achievement Award 2021


C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

3 December 2021 – C4X Discovery Holdings plc (AIM: C4XD), is delighted to announce that its Chief Executive Officer, Dr Clive Dix together with Dame Kate Bingham, the leaders of the UK Vaccine Taskforce, have won the Lifetime Achievement Award at the 2021 Scrip Awards. The Scrip Awards applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare.

Eva-Lotta Allan, Chairman of C4X Discovery, said:

“We are very proud of this significant achievement by both Clive and Kate and we are thankful for the incredibly important work that they and the whole of the UK Vaccine Taskforce have carried out. Throughout his impressive career, Clive has contributed significantly to the industry and to us, at C4XD, his drive and determination to best serve patients is what makes Clive the great leader and CEO that he is and everyone at C4XD is delighted to see them all recognised through the Scrip Lifetime Achievement Award.”

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders.  Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.  Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For more information visit us at
www.c4xdiscovery.com or follow us on twitter @C4XDiscovery